Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Udo Oppermann

Showing results (181-190 of 209) with videos related to

Pageof 21
Sort By:
Ejhaem|May 1, 2025
Belantamab Mafodotin Monotherapy for Multiply-Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of IrelandEdmund C R Watson, Faouzi Djebbari, Fotios Panitsas, et al.
Angewandte Chemie (International Ed. in English)|November 16, 2018
Design, Synthesis and Characterization of Covalent KDM5 InhibitorsSaleta Vazquez-Rodriguez, Miranda Wright, Catherine M Rogers, et al.
Scientific Reports|February 1, 2020
Amine oxidase 3 is a novel pro-inflammatory marker of oxidative stress in peritoneal endometriosis lesionsMarie-Laëtitia Thézénas, Bianca De Leo, Alexis Laux-Biehlmann, et al.
Cell Stem Cell|February 24, 2026
comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disordersYuqi Shen, Camelia Benlabiod, Edmund Watson, et al.
Scientific Reports|March 25, 2020
Author Correction: Amine oxidase 3 is a novel pro-inflammatory marker of oxidative stress in peritoneal endometriosis lesionsMarie-Laëtitia Thézénas, Bianca De Leo, Alexis Laux-Biehlmann, et al.
Epigenetics & Chromatin|March 8, 2017
Assessing histone demethylase inhibitors in cells: lessons learnedStephanie B Hatch, Clarence Yapp, Raquel C Montenegro, et al.
Blood|May 8, 2026
Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapiesLucia Y Chen, Adolfo Aleman, Marta Larrayoz, et al.
Blood Cancer Journal|February 6, 2023
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myelomaKeiji Kurata, Anna James-Bott, Mark A Tye, et al.
Blood Cancer Journal|January 11, 2023
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myelomaKeiji Kurata, Anna James-Bott, Mark A Tye, et al.
Cell Chemical Biology|March 7, 2017
Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma CellsAnthony Tumber, Andrea Nuzzi, Edward S Hookway, et al.
Pageof 21

Showing results (181-190 of 209) with videos related to

Sort By:
Pageof 21
Ejhaem|May 1, 2025
Belantamab Mafodotin Monotherapy for Multiply-Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of IrelandEdmund C R Watson, Faouzi Djebbari, Fotios Panitsas, et al.
Angewandte Chemie (International Ed. in English)|November 16, 2018
Design, Synthesis and Characterization of Covalent KDM5 InhibitorsSaleta Vazquez-Rodriguez, Miranda Wright, Catherine M Rogers, et al.
Scientific Reports|February 1, 2020
Amine oxidase 3 is a novel pro-inflammatory marker of oxidative stress in peritoneal endometriosis lesionsMarie-Laëtitia Thézénas, Bianca De Leo, Alexis Laux-Biehlmann, et al.
Cell Stem Cell|February 24, 2026
comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disordersYuqi Shen, Camelia Benlabiod, Edmund Watson, et al.
Scientific Reports|March 25, 2020
Author Correction: Amine oxidase 3 is a novel pro-inflammatory marker of oxidative stress in peritoneal endometriosis lesionsMarie-Laëtitia Thézénas, Bianca De Leo, Alexis Laux-Biehlmann, et al.
Epigenetics & Chromatin|March 8, 2017
Assessing histone demethylase inhibitors in cells: lessons learnedStephanie B Hatch, Clarence Yapp, Raquel C Montenegro, et al.
Blood|May 8, 2026
Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapiesLucia Y Chen, Adolfo Aleman, Marta Larrayoz, et al.
Blood Cancer Journal|February 6, 2023
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myelomaKeiji Kurata, Anna James-Bott, Mark A Tye, et al.
Blood Cancer Journal|January 11, 2023
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myelomaKeiji Kurata, Anna James-Bott, Mark A Tye, et al.
Cell Chemical Biology|March 7, 2017
Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma CellsAnthony Tumber, Andrea Nuzzi, Edward S Hookway, et al.
Pageof 21